SCHEMBL6865583

SCHEMBL6865583

CC(=O)C1(C)CCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6866082 0.97 ALDH1A1 (0.48)
SCHEMBL12626878 0.97 ALDH1A1 (0.48)
SCHEMBL12660610 0.97 ALDH1A1 (0.48)
SCHEMBL17574280 0.97 ALDH1A1 (0.48)
SCHEMBL14407687 0.97 ALDH1A1 (0.48)
SCHEMBL1662191 0.94
SCHEMBL811021 0.87
SCHEMBL1837402 0.79 FFAR3 (0.48)
SCHEMBL13954105 0.79 FFAR3 (0.48)
SCHEMBL16892256 0.78 FFAR3 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024030651-A1 GPX4 INHIBITORS AND USE THEREOF SONATA THERAPEUTICS, INC. (US) 2024-02-08 WO disclosed
EP-4309741-A1 CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-01-24 EP disclosed
US-20230144324-A1 PCSK9 ANTAGONIST COMPOUNDS MERCK SHARP & DOHME LLC 2023-05-11 US disclosed
US-20210163536-A1 MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN IPSEN PHARMA SAS (FR) 2021-06-03 US disclosed
US-20190111105-A1 Use of Melanocortins to Treat Insulin Sensitivity IPSEN PHARMA S.A.S. (FR) 2019-04-18 US disclosed
EP-3019196-B1 COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-06-06 EP disclosed
US-20180118784-A1 MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN IPSEN PHARMA S.A.S. (FR) 2018-05-03 US disclosed
EP-2802326-B1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-04-18 EP disclosed
US-9845339-B2 Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers RHYTHM PHARMACEUTICALS, INC. (US) 2017-12-19 US disclosed
US-9827286-B2 Use of melanocortins to treat insulin sensitivity IPSEN PHARMA S.A.S. (FR) 2017-11-28 US disclosed
US-20110319422-A1 PRODRUGS OF NH-ACIDIC COMPOUNDS: ESTER, CARBONATE, CARBAMATE AND PHOSPHONATE DERIVATIVES ALKERMES, INC. (US) 2011-12-29 US disclosed
WO-2011017209-A1 USE OF MELANOCORTINS TO TREAT DYSLIPIDEMIA IPSEN PHARMA S.A.S. (FR) 2011-02-10 WO disclosed
US-20100317848-A1 PROCESS FOR THE SYNTHESIS OF DERIVATIVES OF 3-AMINO-TETRAHYDROFURAN-3-CARBOXYLIC ACID AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-16 US disclosed
US-20100311647-A1 USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY IPSEN PHARMA S.A.S. (FR) 2010-12-09 US disclosed
US-20100184646-A1 MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN IPSEN PHARMA S.A.S. (FR) 2010-07-22 US disclosed
WO-2009061411-A2 USE MELANOCORTINS TO TREAT INSULIN SENSITIVITY IPSEN PHARMA S.A.S. (FR) 2009-05-14 WO disclosed
WO-2008147556-A2 MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN IPSEN PHARMA S.A.S. (FR) 2008-12-04 WO disclosed
EP-1043298-A1 PROCESSES FOR THE PREPARATION OF ALCOHOLS Daicel Chemical Industries, Ltd. (JP) 2000-10-11 EP disclosed
EP-0021525-B1 PROCESS FOR THE PREPARATION OF CARBOXYLATED COMPOUNDS INTEROX Société Anonyme (BE) 1984-02-29 EP disclosed
US-4353832-A OXIDATION OF CARBONYL COMPOUND TO CARBOXYL COMPOUND IN PRESENCE OF CATALYST AND ABSENCE OF WATER INTEROX (SOCIETE ANONYME) (BE) 1982-10-12 US disclosed